Novel antigen-specific immunomodulatory tregitope-based therapy to address autoimmune pathogenesis in graves' disease
Ended Project Grant Awarded Last action
- Award ID
- R43DK115365
- Recipient
-
Epivax Inc. UEI NLAVQM513F18
- Awarding agency
-
National Institutes of Health
Department of Health and Human Services
- Obligated
- $316,862
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Place of performance
- Downtown Providence, Providence, RI, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $139,842 | |
| Original award | $177,020 |
Quick answers
Who received award R43DK115365?
R43DK115365 was awarded to Epivax Inc. by National Institutes of Health (Department of Health and Human Services) on September 1, 2017.
How much is award R43DK115365 worth?
$316,862 has been obligated on R43DK115365.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award